Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q, which are available at www.sec.gov.
CASI - Highlights

LAUNCHING MEDICINES USING GLOBAL DEVELOPMENT MODEL WITH CHINA AS INITIAL COMMERCIAL FOCUS

• EVOMELA® launched in China
  • Commercial team of 70+ hematology oncology specialists

• CNCT19: CD19 CAR-T Cell Therapy
  • Through our collaboration with Juventas Cell Therapy Ltd, potentially be among first to locally develop, manufacture, and commercialize a non-imported CD19 CAR-T therapy in China, at substantially lower cost than imported therapies
  • Interim data in investigator trial show total CR/CRi rate 90% at day 28 (n=20)
  • Registration trials by our partner Juventas to start Q1 2021
  • China marketing approval targeted by Juventas for Q4 2022
  • Current CASI commercial team already specialized in hematology oncology and established with key hospitals, KOLs, and pharmacies

• CID-103: Anti-CD38 mAb
  • Phase 1 trial expected to start in Q1 2021
## Pipeline

### CHINA DEVELOPED INNOVATIVE CELL THERAPY WITH GLOBAL COMMERCIAL RIGHTS

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>IN-LICENSED (Commercial Rights)</th>
<th>CTA FILING &amp; REVIEW</th>
<th>PHASE 1</th>
<th>PHASE 2 REGISTRATION TRIAL</th>
<th>NDA FILING &amp; REVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNTC19 (Autologous Anti-CD19 T-cell therapy)</td>
<td>Hematological Malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### INVESTIGATIONAL INNOVATIVE DRUG CANDIDATE WITH GLOBAL IP AND COMMERCIAL RIGHTS

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>PRE-CLINICAL</th>
<th>IND/IMPD</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CID-103 (Anti-CD 38 mAb)</td>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### U.S. FDA-APPROVED PRODUCTS IN-LICENSED FOR GREATER CHINA REGION

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>IN-LICENSED</th>
<th>CTA FILING &amp; REVIEW</th>
<th>PHASE 2 REGISTRATION TRIAL</th>
<th>NDA FILING &amp; REVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVOMELA®</td>
<td>IN-LICENSED</td>
<td>CTA FILING &amp; REVIEW</td>
<td>PHASE 2 REGISTRATION TRIAL</td>
<td>NDA FILING &amp; REVIEW</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZEVALIN®</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hodgkin's Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MARQIBO®</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Lymphoblastic Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Launched and commercially available in China*

### EU-APPROVED PRODUCT IN-LICENSED FOR CHINA

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>IN-LICENSED</th>
<th>CTA FILING &amp; REVIEW</th>
<th>PHASE 2 REGISTRATION TRIAL</th>
<th>NDA FILING &amp; REVIEW</th>
</tr>
</thead>
<tbody>
<tr>
<td>Octreotide LAI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms associated with neuroendocrine cancers and acromegaly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiotepa</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematological Malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) Clinical development is the responsibility of Juventas Cell Therapy Ltd., a China-based domestic company.
EVOMELA® Launched in China

- Launched in mid-August 2019 – $4.1 million revenue at year end 2019, $6 million revenue for first half of 2020, with full-year forecast of a minimum of $10 million
- Post-marketing study initiated
- Only form of melphalan commercially available in China
- Used in preparative regimen for autologous stem cell transplant (ASCT), 1st line treatment for multiple myeloma. Provides best choice due to:
  - Lack of propylene glycol solvent
  - Stability and improved handling for pharmacists/nurses/physicians
EVOMELA® Market Potential in China

• Potential patient pool in China market: ~ 12,000-18,000 patients

CNCT19
(CD19 CAR-T Cell Therapy)
CNCT19 – A Validated Target

- Targets CD19, a B-cell surface protein widely expressed during all phases of B-cell development and validated target for B-cell derived hematological malignancies.

- CD19-targeted CAR therapies have demonstrated consistently high antitumor efficacy in children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (B-NHL).
CNCT19 – Validated in Investigator Study

• Interim data presented at ASH\(^{(1)}\) by principal investigator\(^{(2)}\) from a phase I clinical trial conducted to evaluate the safety and efficacy of CNCT19 in patients with relapsed refractory (R/R) acute lymphoblastic leukemia
  - 20 patients treated with CD19 CART cells and included in study analysis

• **Total CR/CRi rate was \(\sim 90\%\) at day 28**, in which MRD negative CR/CRi rate was \(\sim 70\%\)

• After median follow-up of 17 months (range, 0.2-19.8), the **median OS** for the entire cohort of patients was 9.6 months (\(\sim 95\%\) CI, 4.2-15.0), and the median RFS was 9 months (\(\sim 95\%\) CI, 6.7-11.3)

• The report concluded that CNCT19 has potent anti-leukemia activities in patients with R/R B-ALL

---

\(^{(1)}\) American Society of Hematology (ASH), December 2019

\(^{(2)}\) From the Institute of Hematology, Chinese Academy of Medical Sciences
**CNCT19 – Juventas Development and Launch Timeline**

Phase 1 trials in R/R B-cell Non-Hodgkin lymphoma (B-NHL) and R/R B-cell acute lymphoblastic leukemia (B-ALL) are currently enrolling in China.

<table>
<thead>
<tr>
<th>December 2019</th>
<th>March 2020</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B-NHL Phase 1</td>
<td>Phase 2 / Registration Trial</td>
<td>NDA Filing</td>
<td>Approval</td>
</tr>
<tr>
<td></td>
<td>B-ALL Phase 1</td>
<td>Phase 2 / Registration Trial</td>
<td>NDA Filing</td>
<td>Approval</td>
</tr>
</tbody>
</table>

NMPA Approval
CNCT19 – China Market Opportunity

- Potential patient pool in China market: ~39,000-51,000 patients (including ~6,000-6,900 CD19-positive R/R B-cell acute lymphoblastic leukemia (ALL) and ~33,000-44,000 CD19-positive R/R invasive B-cell Non-Hodgkin’s Lymphoma (NHL)

CNCT19 – Significant Value Inflection Point

• Through our collaboration with Juventas, potentially be among first to locally develop, manufacture and commercialize a non-imported CD19 CAR-T therapy in China at substantially lower cost than imported therapies

• Interim data in investigator trial show total CR/CRi rate 90% at day 28 (n=20)

• Registration trials to start by Q1 2021

• China marketing approval targeted by Juventas for Q4 2022

• Commercial team of 70+ hematology oncology specialists and established with key hospitals, pharmacies and KOLs
CID-103
(Fully human IgG1 anti-CD38 monoclonal antibody)
CID-103: Fully human IgG1 anti-CD38 monoclonal antibody

- Exclusive global rights
- Phase 1 trial target expected to start in Q1 2021
- Fully human IgG1 anti-CD38 mAb recognizing a unique epitope
- No overt infusion related reactions observed
- Encouraging preclinical efficacy & safety profile compared to other anti-CD38 mAbs

- Demonstrates greater antibody-dependent cellular cytotoxicity (ADCC) activity over Daratumumab and other anti-CD38 mAbs
- In vivo activity outperforms Daratumumab and other anti-CD38 mAbs
- Survival improvement observed in Daudi, Ramos and Raji Xenograft models
CID-103 (TSK011010) Demonstrates Higher ADCC Activity over Darzalex and Isatuximab

Sources: AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3812. TUSK Therapeutics Internal Reports
CID-103 (TSK011010) Demonstrates Survival Advantage over Competitor CD-38 mAbs

**Experimental details:** CB17 SCID mice, n=8/group
- do i.v. injection Daudi, Ramos or Raji cells
- 10mg/kg for each Ab i.p., start d5, twice a week for 3 weeks.

**TSo11010 in vivo activity outperforms Darzalex, Isatuximab and MOR-202**

- TSK011010 shows strong therapeutic activity against B cell lymphomas
- TSK011010 ensures higher survival rate than Darzalex in Daudi, Ramos and Raji models
- Higher survival rate than Research grade “Isatuximab” and “Mor202” in Ramos model

Sources: AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3812. TUSK Therapeutics Internal Reports
No Overt Infusion Related Reactions Observed with CID-103 (TSK011010) in Cynomolgus Monkeys

- Non-GLP Non-Human Primate Dose Range Finding Study:
  - No immediate systemic reaction (cytokine-release like syndrome) observed (16 animals dosed 0.03 to 10 mg/kg) in the Dose-Range Study in Cynomolgus monkeys

- GLP Non-Human Primate Toxicity Study:
  - No clinical observations suggesting an Infusion Related Reaction in any animal in the GLP Toxicology Study (32 Cynomolgus monkeys tested)

Sources: Tusk Therapeutics Internal Reports
Rapid Growth of Anti-CD38 Market

Blockbuster Darzalex surpasses $3B in Annual Sales

- Daratumumab (J&J’s Darzalex®) approved in U.S. and EU for Multiple Myeloma (FDA 2015; EMA 2016) - Over $3 billion in annual sales
- Isatuximab (Sanofi’s Sarclisa®) approved in U.S. for R/R Multiple Myeloma (March 2020)
- Investigational anti-CD38 antibodies:
  - Mor202 (Morphosys) Phase 3
  - TAK079 (Takeda) Phase 1/2
  - GBR 1342 (Glenmark) bispecific in Phase 1

Sources: Genmab A/S Press Releases, BioCentury
CID-103 – Multiple Myeloma Market Opportunity

- **USA**: 32,270 new cases /year; 5 year prevalence of 84,000
- **China**: 20,100 new cases/year; 5 year prevalence of 44,643
- **Worldwide**: 140,000 new cases per/year

Sources: JAMA Oncol. 2018;4(9):1221–1227; CA CANCER J CLIN 2020;70:7–30
Other Assets with Near-Term Targets
Other Assets

Octreotide Long Acting Injectable (LAI)
- Exclusive China rights
- Octreotide LAI formulations considered a standard of care for the treatment of acromegaly and the control of symptoms associated with certain neuroendocrine tumors
- Approved in various European countries
- China registration study – expect initiation in 2020

ZEVALIN®
- Exclusive greater China rights
- CD20-directed radiotherapeutic antibody for treatment of patients with R/R, low-grade or follicular B-cell non-Hodgkin’s lymphoma (FNHL) and patients with previously untreated follicular non-Hodgkin’s Lymphoma (FNHL)
- Approved and commercialized in the U.S.
- China registration study – expect initiation in early 2021

Thiotepa
- Exclusive China rights
- Conditioning treatment for allogeneic haemopoietic stem cell transplants (EMA)
- China registration study – expect initiation in 2021
Management and Recap
Recap of Key Activities and Objectives for 2020-2021

- **EVOMELA®**
  - Manage cost of goods and continue to drive sales

- **CNCT19 (CD19 CAR-T Cell Therapy)**
  - Phase 1 study completion by our partner Juventas in Q1 2021
  - Registration trials initiation by our partner Juventas in Q1 2021

- **CID-103 (potential best-in-class anti-CD38 mAb)**
  - Initiate phase I study in Q1 2021

- **Octreotide (LAI)**
  - Initiate China registration study in 2020

- **ZEVALIN®**
  - Initiate China registration study in early 2021

- **Thiotepa novel formulation**
  - Initiate China registration study in 2021

- **Business development – additional assets for pipeline**

- **Phase 1 construction of GMP manufacturing facility in Wuxi, China**